{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:51:38Z","timestamp":1787197898431,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["847949"],"award-info":[{"award-number":["847949"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["FRM EQU202303016287"],"award-info":[{"award-number":["FRM EQU202303016287"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-18-CE14-0006-01"],"award-info":[{"award-number":["ANR-18-CE14-0006-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jtha.2024.06.029","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T12:51:24Z","timestamp":1723121484000},"page":"3479-3489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Anticoagulation for splanchnic vein thrombosis in myeloproliferative neoplasms: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5107-8340","authenticated-orcid":false,"given":"Pavlina","family":"Chrysafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Barnum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve M.","family":"Gerhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thita","family":"Chiasakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshit","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Mcnichol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Semmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Rautou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy N.","family":"Lauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Zwicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8426-3398","authenticated-orcid":false,"given":"Rushad","family":"Patell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.06.029_bib1","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3904\/kjim.2020.634","article-title":"Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm","volume":"36","author":"Song","year":"2021","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jtha.2024.06.029_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A\u00a0systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtha.2024.06.029_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106809","article-title":"Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia","volume":"115","author":"Pemmaraju","year":"2022","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtha.2024.06.029_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.06.029_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3324\/haematol.2010.038299","article-title":"Pathophysiology of thrombosis in myeloproliferative neoplasms","volume":"96","author":"Landolfi","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.06.029_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11899-017-0400-3","article-title":"Risk factors for and management of MPN-associated bleeding and thrombosis","volume":"12","author":"Martin","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jtha.2024.06.029_bib7","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-21-1140","article-title":"Circulating protein disulfide isomerase is associated with increased risk of thrombosis in JAK2-mutated myeloproliferative neoplasms","volume":"27","author":"Sharda","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtha.2024.06.029_bib8","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/jth.12265","article-title":"Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management","volume":"11","author":"Casini","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.029_bib9","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1055\/s-0038-1667015","article-title":"Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features","volume":"118","author":"Guadall","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.029_bib10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2(V617F) is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.06.029_bib11","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1111\/jth.15095","article-title":"Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm","volume":"18","author":"Castiglione","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.029_bib12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/01.RES.0000255690.03436.ae","article-title":"Phenotypic heterogeneity of the endothelium: II. Representative vascular beds","volume":"100","author":"Aird","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.jtha.2024.06.029_bib13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/VHRM.S197732","article-title":"Splanchnic vein thrombosis: current perspectives","volume":"15","author":"Valeriani","year":"2019","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jtha.2024.06.029_bib14","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.2020006827","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis","volume":"137","author":"Valeriani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.029_bib15","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1182\/blood-2014-07-551515","article-title":"How I treat splanchnic vein thrombosis","volume":"124","author":"Ageno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.06.029_bib16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.thromres.2017.06.030","article-title":"Clinical manifestations and imaging tools in the diagnosis of splanchnic and cerebral vein thromboses","volume":"163","author":"Riva","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.06.029_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2040620716680333","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease","volume":"8","author":"How","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtha.2024.06.029_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/cancers15010011","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment considerations and unmet needs","volume":"15","author":"Liu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtha.2024.06.029_bib19","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.06.029_bib20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtha.2024.06.029_bib21","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1111\/j.1572-0241.2007.01477.x","article-title":"Prognostic factors in noncirrhotic patients with splanchnic vein thromboses","volume":"102","author":"Amitrano","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jtha.2024.06.029_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2022.08.003","article-title":"Splanchnic vein thrombosis associated with myeloproliferative neoplasms","volume":"218","author":"Tremblay","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.06.029_bib23","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.06.029_bib24","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1182\/bloodadvances.2022007961","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis","volume":"6","author":"Candeloro","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.06.029_bib25","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.jtha.2024.06.029_bib26","first-page":"5","article-title":"Splanchnic vein thrombosis (SVT) in patients with myeloproliferative (MPN) neoplasms [abstract]","volume":"173","author":"Danaee","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2024.06.029_bib27","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.cgh.2022.04.024","article-title":"Outcome of Budd-Chiari syndrome patients treated with direct oral anticoagulants: an Austrian multicenter study","volume":"21","author":"Semmler","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jtha.2024.06.029_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/0268355518779517","article-title":"Evaluation of direct oral anticoagulants and vitamin K antagonists in mesenteric venous thrombosis","volume":"34","author":"Salim","year":"2019","journal-title":"Phlebology"},{"key":"10.1016\/j.jtha.2024.06.029_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12959-018-0187-z","article-title":"Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms - long term follow-up of a regional case series","volume":"16","author":"Greenfield","year":"2018","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2024.06.029_bib30","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients","volume":"6","author":"De Stefano","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtha.2024.06.029_bib31","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2015.3184","article-title":"Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry","volume":"175","author":"Ageno","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtha.2024.06.029_bib32","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/jth.12930","article-title":"Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study","volume":"13","author":"Riva","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.029_bib33","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/j.1538-7836.2011.04484.x","article-title":"Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms","volume":"9","author":"Hoekstra","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.029_bib34","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/bloodadvances.2022007397","article-title":"Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study","volume":"6","author":"Ageno","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.06.029_bib35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jhep.2010.06.019","article-title":"Bleeding in patients with Budd-Chiari syndrome","volume":"54","author":"Rautou","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtha.2024.06.029_bib36","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1182\/bloodadvances.2020002414","article-title":"Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses","volume":"4","author":"Debureaux","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.06.029_bib37","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1002\/alz.12976","article-title":"Pathways explaining racial\/ethnic disparities in incident all-cause dementia among middle-aged US adults","volume":"19","author":"Weiss","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.jtha.2024.06.029_bib38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases","volume":"95","author":"Sant'Antonio","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.06.029_bib39","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200104","article-title":"Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis","volume":"1","author":"Plessier","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jtha.2024.06.029_bib40","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/STROKEAHA.116.013343","article-title":"Anticoagulant-associated intracranial hemorrhage in the era of reversal agents","volume":"48","author":"Steiner","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2024.06.029_bib41","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/STROKEAHA.116.016275","article-title":"Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis","volume":"48","author":"Bai","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2024.06.029_bib42","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1177\/17474930231175807","article-title":"Risk of both intracranial hemorrhage and ischemic stroke in elderly individuals with nonvalvular atrial fibrillation taking direct oral anticoagulants compared with warfarin: analysis of the ANAFIE registry","volume":"18","author":"Shiozawa","year":"2023","journal-title":"Int J Stroke"},{"key":"10.1016\/j.jtha.2024.06.029_bib43","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/jth.14131","article-title":"A\u00a0systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants","volume":"16","author":"Wolfe","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.029_bib44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jtha.2023.10.011","article-title":"Comparison of direct oral anticoagulants versus low-molecular-weight heparin in primary and metastatic brain cancers: a meta-analysis and systematic review","volume":"22","author":"Iyengar","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.06.029_bib45","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MEG.0000000000002035","article-title":"Major gastrointestinal bleeding risk with direct oral anticoagulants: Does type and dose matter? - a systematic review and network meta-analysis","volume":"33","author":"Radadiya","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jtha.2024.06.029_bib46","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3748\/wjg.v23.i11.1954","article-title":"Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management","volume":"23","author":"Cheung","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jtha.2024.06.029_bib47","first-page":"279","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"149","author":"Joosten","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2024.06.029_bib48","article-title":"Management of splanchnic vein thrombosis","volume":"5","author":"Elkrief","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jtha.2024.06.029_bib49","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00277-017-3099-2","article-title":"The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review","volume":"96","author":"Kc","year":"2017","journal-title":"Ann Hematol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T03:17:17Z","timestamp":1764559037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624004422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1538783624004422"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.06.029","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation for splanchnic vein thrombosis in myeloproliferative neoplasms: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}